Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Novel Agents Show Early Promise in HCC

Silas Inman @silasinman
Published: Tuesday, Jul 14, 2015

A collection of early phase clinical trials presented at the 2015 ASCO Annual Meeting demonstrated promising results for several novel agents in combination with established treatments for patients with hepatocellular carcinoma (HCC).


  1. Duffy AG, Ma C, Ulahannan SV, et al. A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC). J Clin Oncol. 2015;33 (suppl; abstr 4083).
  2. Duffy AG, Makarova-Rusher OV, Kerkar SP, et al. A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2015;33 (suppl; abstr 4081).
  3. Chan SL, Yeo W, Mo F, et al. A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response. J Clin Oncol. 2015;33 (suppl; abstr 4073)

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication